Fintel reports that on May 26, 2023, Credit Suisse reiterated coverage of 23andMe Holding Co – (NASDAQ:ME) with a Outperform recommendation.
Analyst Price Forecast Suggests 178.91% Upside
As of May 11, 2023, the average one-year price target for 23andMe Holding Co – is 5.80. The forecasts range from a low of 3.79 to a high of $7.35. The average price target represents an increase of 178.91% from its latest reported closing price of 2.08.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for 23andMe Holding Co – is 297MM, a decrease of 3.63%. The projected annual non-GAAP EPS is -0.75.
What is the Fund Sentiment?
There are 303 funds or institutions reporting positions in 23andMe Holding Co -. This is an increase of 13 owner(s) or 4.48% in the last quarter. Average portfolio weight of all funds dedicated to ME is 0.28%, an increase of 18.84%. Total shares owned by institutions increased in the last three months by 0.51% to 139,558K shares. The put/call ratio of ME is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
NewView Capital Partners I holds 19,456K shares representing 4.25% ownership of the company. No change in the last quarter.
Euclidean Capital holds 10,243K shares representing 2.24% ownership of the company. No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 8,502K shares representing 1.86% ownership of the company. No change in the last quarter.
NAESX – Vanguard Small-Cap Index Fund Investor Shares holds 7,159K shares representing 1.57% ownership of the company. In it’s prior filing, the firm reported owning 7,018K shares, representing an increase of 1.97%. The firm increased its portfolio allocation in ME by 3.35% over the last quarter.
Alphabet holds 6,737K shares representing 1.47% ownership of the company. No change in the last quarter.
23andMe Holding Background Information
(This description is provided by the company.)
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.